Please try another search
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company’s lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn’s disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Richard N. Kender | 68 | 2014 | Independent Director |
Eric D. Shaff | 48 | 2014 | President, CEO & Director |
Dennis Arthur Ausiello | 79 | 2015 | Independent Director |
Mark H. Wilcox | - | 2015 | Member of Scientific Advisory Board |
Andrew Goodman | - | - | Member of Scientific Advisory Board |
Curtis Huttenhower | - | - | Member of Scientific Advisory Board |
Willard H. Dere | 70 | 2017 | Independent Director |
Kurt C. Graves | 56 | 2015 | Independent Director |
Stephen A. Berenson | 63 | 2019 | Independent Chairman |
Claire M. Fraser-Liggett | 69 | 2023 | Independent Director |
Paul R. Biondi | 54 | 2020 | Independent Director |
Robert Jenq | - | - | Member of Scientific Advisory Board |
Marcel R.M. van den Brink | - | - | Member of Scientific Advisory Board |
Elhanan Borenstein | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review